In line with the observation of Tanabe et al. (2020), where in CML BM-MKs correlated with BCR::ABL1 copy number after TKI treatment, we could speculate that the persistence of this MK population might represent an obstacle for the success of TFR. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.